

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-E-H246
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Performed: 27/02/2023
Complete: Final

Date Requested: 7/02/2023
Date Collected: 27/02/2023
Specimen:
Subject(Test Name): B12/FOLATE/RCF
Clinical Information:

Clinical Notes : BRINTELLIX

VIT B12 & FOLATE

Date	Time F-Fast	Lab ID	Vitamin B12	S.Fol (Abbott)	Units	Reference
25/06/15		0922 F	459	291		
19/11/19		1349	29.2	12.1		
04/03/22		1042 F	316	16.2		
27/02/23		0809 F	20.3		pmol/L	(135-550)
		293830962			nmol/L	(>7.0)



Tests Completed: HbA1c(s), LFT(s), Urea(s), Creat(s), E(s), Glu(s), Iron(s),
Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(s)
Tests Pending :
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-C205
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): LIPIDS HDL(S)
Clinical Information:

Clinical Notes : BRINTELLIX

Date	09/10/13	25/06/15	04/03/22	27/02/23		
Time F-Fast	0945 F	0922 F	1042 F	0809 F		
Lab ID	278044425	248668507	869150740	293830962	Units	Reference
Status	Fasting	Fasting	Fasting	Fasting		
Cholesterol	4.1	L 3.4	4.2	3.7	mmol/L	(<5.5)
Triglycerides	1.0	0.8	1.0	0.9	mmol/L	(<2.0)
HDL Chol.	1.6	1.5	1.4	1.4	mmol/L	(>1.2)
LDL Chol.	2.0	L 1.5	2.3	1.9	mmol/L	(<3.0)
Non-HDL Chol.				2.3	mmol/L	(<4.0)

Comments on Collection 27/02/23 0809 F:

Please note that the above reference limits are decision limits.
A flag based on these limits is an indication to review the absolute cardiovascular risk for the patient. For assessment of absolute cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Consensus Statement 2016 and the Australasian Association of Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

Please note that as there is a continuum of risk, benefits are obtained for any measured lipid components moving towards and beyond the various target levels.

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), FBC(e)
Tests Pending : FOL(s), Iron(s), Vit D(s), TSH(s), Active B12(s)
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-C141
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): BIOCHEMISTRY
Clinical Information:

Clinical Notes : BRINTELLIX

BIOCHEMISTRY

Date	04/03/22	09/06/22	26/10/22	27/02/23		
Time F-Fast	1042 F	1005 F	1012 F	0809 F		
Lab ID	869150740	881042506	882527917	293830962	Units	Reference
Status	Fasting	Fasting		Fasting		
Sodium	140	138	138	140	mmol/L	(135-145)
Potassium	4.6	4.2	4.4	4.8	mmol/L	(3.5-5.5)
Chloride	107	105	106	107	mmol/L	(95-110)
Bicarbonate	27	26	23	23	mmol/L	(20-32)
Urea	4.8	5.7	6.2	6.5	mmol/L	(2.5-7.0)
Creatinine	65	65	60	65	umol/L	(45-85)
eGFR	>90	>90	>90	>90	mL/min/1.73m2	(>59)
Bili.Total	6	7	6	3	umol/L	(3-15)
ALP	75	73	65	75	U/L	(20-105)
GGT	17	H 38	33	20	U/L	(5-35)
LD	179	194	160	181	U/L	(120-250)
AST	15	19	15	13	U/L	(10-35)
ALT	14	25	15	14	U/L	(5-30)
Total Protein	68	68	L 66	L 67	g/L	(68-85)
Albumin	40	41	41	42	g/L	(37-48)
Globulin	28	27	25	25	g/L	(23-39)
Cholesterol	4.2	L 3.8		3.7	mmol/L	(<5.5)
Triglycerides	1.0	0.9		0.9	mmol/L	(<2.0)

Comments on Collection 27/02/23 0809 F:

eGFR (mL/min/1.73m2) calculated by CKD-EPI formula - see www.kidney.org.au

NATA Accreditation No 2178

Tests Completed: LFT(s),C(s),UCreat(s),E(s),Glu(p),Lipids HDL(s),FBC(e)
Tests Pending : Fol(s),Iron(s),Vit D(s),TSH(s), Active B12(s)
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-C924
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): _GLUCOSE
Clinical Information:

Clinical Notes : BRINTELLIX

GLUCOSE

Date	25/06/15	04/03/22	09/06/22	27/02/23		
Time F-Fast	0922 F	1042 F	1005 F	0809 F		
Lab ID	248668507	869150740	881042506	293830962	Units	Reference
F Gluc Plasma		5.3	5.2	5.3	mmol/L	(3.6-6.0)
F Gluc Serum	5.1				mmol/L	(3.6-6.0)

Comments on Collection 27/02/23 0809 F:
Diabetes is unlikely if fasting glucose levels are less than 5.5 mmol/L but an OGTT could be indicated in the presence of risk factors such as metabolic syndrome, past gestational diabetes, polycystic ovary or family history of type 2 diabetes.

NATA Accreditation No 2178

Tests Completed: Glu(p),FBC(e)
Tests Pending : Fol(s),LFT(s),C(s),UCreat(s),E(s),Iron(s),
Lipids HDL(s),Vit D(s),TSH(s), Active B12(s)
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-H-H902
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): HAEMATOLOGY
Clinical Information:

Clinical Notes : BRINTELLIX

HAEMATOLOGY

Date	04/03/22	09/06/22	26/10/22	27/02/23		
Time F-Fast	1042 F	1005 F	1012 F	0809 F		
Lab ID	869150740	881042506	882527917	293830962	Units	Reference
Haemoglobin	129	123	127	125	g/L	(119-160)
RCC	4.9	4.6	4.9	4.7	x10 ¹² /L	(3.8-5.8)
Haematocrit	0.41	0.39	0.41	0.39		(0.35-0.48)
MCV	83	84	84	84	fL	(80-100)
MCH	L 26.4	L 26.5	L 25.9	L 26.6	pg	(27.0-32.0)
MCHC	317	315	310	318	g/L	(310-360)
RDW	14.8	15.0	H 16.5	H 15.4		(10.0-15.0)
WCC	6.3	6.0	5.9	5.9	x10 ⁹ /L	(4.0-11.0)
Neutrophils	4.25	4.21	4.01	3.82	x10 ⁹ /L	(2.0-7.5)
Lymphocytes	1.52	1.28	1.42	1.63	x10 ⁹ /L	(1.0-4.0)
Monocytes	0.36	0.38	0.41	0.35	x10 ⁹ /L	(0.0-1.0)
Eosinophils	0.07	0.06	0.03	0.09	x10 ⁹ /L	(0.0-0.5)
Basophils	0.06	0.04	0.04	0.03	x10 ⁹ /L	(0.0-0.3)
NRBC	<1.0	<1.0	<1.0	<1.0	/100 WBC	(<1)
Platelets	387	383	362	375	x10 ⁹ /L	(150-450)

Comments on Collection 27/02/23 0809 F:
Borderline / low red cell indices.
Possible causes include iron deficiency and thalassaemia trait /
haemoglobinopathy.

NATA Accreditation No 2178

Tests Completed: FBC(e)
Tests Pending : Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Iron(s),
Lipids HDL(s), Vit D(s), TSH(s), Active B12(s)
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-E348
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023
Specimen:

Date Performed: 27/02/2023
Complete: Final

Subject(Test Name): ACTIVE B12(S)
Clinical Information:

Clinical Notes : BRINTELLIX

Date	19/11/19	04/03/22	27/02/23		
Time F-Fast	1349	1042 F	0809 F		
Lab ID	299698275	869150740	293830962	Units	Reference
Active B12	76	123	>128	pmol/L	(>35)

NATA Accreditation No 2178

Tests Completed: Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Iron(s),
Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(e)
Tests Pending :
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-E-E031

Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): THYROID FUNCTION
Clinical Information:

Clinical Notes : BRINTELLIX

TFT

Date	19/11/19	04/03/22	09/06/22	27/02/23		
Time F-Fast	1349	1042 F	1005 F	0809 F		
Lab ID	299698275	869150740	881042506	293830962	Units	Reference
TSH	1.50	1.90	1.46	1.52	mIU/L	(0.40-3.50)
Free T4			12.9		pmol/L	(9.0-19.0)

NATA Accreditation No 2178

Tests Completed: Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Iron(s),
Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(e)
Tests Pending :
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-C513
Addressee: DR CECILIA ROWE

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Requested: 7/02/2023
Date Collected: 27/02/2023

Date Performed: 27/02/2023
Complete: Final

Specimen:
Subject(Test Name): VIT D(S)
Clinical Information:

Clinical Notes : BRINTELLIX

Date	25/06/15	19/11/19	04/03/22	27/02/23		
Time F-Fast	0922 F	1349	1042 F	0809 F		
Lab ID	248668507	299698275	869150740	293830962	Units	Reference
Vitamin D	66	82	64	81	nmol/L	(50-140)

Comments on Collection 27/02/23 0809 F:
According to the Position Statement 'Vitamin D and health in adults in Australia and New Zealand' MJA, 196(11):686-687, 2012, Vitamin D status is defined as:

Mild Deficiency	30	-	49 nmol/L
Moderate Deficiency	12.5	-	29 nmol/L
Severe Deficiency	<12.5		nmol/L

Vitamin D adequacy can be defined as a level >49 nmol/L at the end of winter - the level may need to be 10 - 20 nmol/L higher at the end of summer, to allow for seasonal decrease.
From 1st November 2014, Medicare rebates for vitamin D testing will apply to patients at risk of Vitamin D deficiency such as chronic lack of sun exposure.

NATA Accreditation No 2178

Tests Completed: Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Iron(s),
Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(e)
Tests Pending :
Sample Pending :

Patient Name: HAHN, VANESSA
Patient Address: 34 POWELL ST, BLAXLAND 2774
D.O.B: 28/04/1977
Medicare No.: 2438556182
Lab. Reference: 293830962-C-C151
Addressee: DR CECILIA ROWE

Date Requested: 7/02/2023
Date Collected: 27/02/2023
Specimen:
Subject(Test Name): IRON STUDIES
Clinical Information:

Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe

Date Performed: 27/02/2023
Complete: Final

Clinical Notes : BRINTELLIX

IRON

Date	11/02/11	09/10/13	19/11/19	27/02/23		
Time F-Fast	0935 F	0945 F	1349	0809 F		
Lab ID	206897272	278044425	299698275	293830962	Units	Reference
Iron	7.6	18.3	12.7	5.4	umol/L	(5.0-30.0)
Transferrin	2.6	3.4	2.3	2.6	g/L	(2.0-3.6)
TIBC (Calc)	58	74	52	58	umol/L	(46-77)
Saturation	13	25	24	L 9	%	(10-45)
Ferritin	43	81	77	26	ug/L	(15-200)

Comments on Collection 27/02/23 0809 F:
 Serum ferritin levels between 15-30 ug/L may reflect depleted iron stores
 and iron therapy may be indicated.

NATA Accreditation No 2178

Tests Completed: Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Iron(s),
 Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(e)
 Tests Pending :
 Sample Pending :